RxDoctor Payments Data

Kathryn Hannigan

Nurse Practitioner · Saint Louis, MONPI 1811318041

Payments from drug & device makers

$1,201in general payments, 2019–2025

Across 52 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$314
  • Astellas Pharma US Inc$290
  • Viiv Healthcare Company$224
  • AbbVie$183
  • Mayne Pharma Commercial LLC$87
  • Paratek Pharmaceuticals, Inc.$73
  • plus $30 from 1 others

What the payments were for

  • Food & beverage$88173%
  • Education$32027%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,201 in reported general payments places this provider in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$22,753
Medicare patients
69
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala587$2,322,258
GenvoyaElviteg/Cob/Emtri/Tenof Alafen138$611,571
OdefseyEmtricitab/Rilpiviri/Tenof Ala134$509,636
TivicayDolutegravir Sodium178$487,125
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf88$406,173
CabenuvaCabotegravir/Rilpivirine48$305,820
NuzyraOmadacycline Tosylate13$203,527
JulucaDolutegravir/Rilpivirine55$193,298
PrezcobixDarunavir/Cobicistat56$144,150
DescovyEmtricitabine/Tenofov Alafenam54$120,705
RukobiaFostemsavir Tromethamine13$110,102
DelstrigoDoravirine/Lamivu/Tenofov Diso31$85,707
PifeltroDoravirine43$73,941
DovatoDolutegravir Sodium/Lamivudine20$58,508
TriumeqAbacavir/Dolutegravir/Lamivudi11$46,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Cabenuva, Juluca, Rukobia, Dovato$224$1,201,849325 claims
Paratek Pharmaceuticals, Inc.Nuzyra$73$203,52713 claims
MerckDelstrigo, Pifeltro, Isentress, Januvia$314$191,044102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →